新型冠状病毒S1蛋白亲和多肽的筛选与验证

Screening and verification of affinity peptide for SARS-CoV-2 spike 1 protein

目的以新型冠状病毒(SARS-CoV-2)刺突蛋白(S1蛋白)为靶点,筛选抗新冠病毒的多肽类药物。方法以S1蛋白为靶蛋白,利用噬菌体展示技术,从噬菌体随机12肽库中筛选亲和多肽,通过酶联免疫吸附实验(ELISA)验证筛选多肽与靶蛋白的亲和性,并对筛选出的亲和多肽进行细胞水平验证。结果多肽p27与S1蛋白具有较强亲和性,并有阻止SARS-CoV-2假病毒进入细胞的作用,IC50为73μmol/L。结论多肽p27可能有抗SARS-CoV-2活性,具有开发成抗新冠病毒多肽类药物的潜力。

Objective To use SARS-CoV-2 spike protein(S protein)as the target to screen anti-SARS-CoV-2-peptide drugs.Methods The SARS-CoV-2 spike protein binding peptides were screened out through affinity selection from a 12-peptide display library,the affinity between the peptides and S protein was verified by enzyme linked immunosorbent assay(ELISA),and the anti-SARS-CoV-2 activity was evaluated in HEK-293T-ACE2 cells.Results p27 had a strong affinity with S1 protein and could prevent SARS-CoV-2 pseudovirus from entering cells with IC50of73μmol/L.Conclusion Peptide p27 may have anti-SARS-COV-2 activity and can be potentially developed into antiSARS-CoV-2.